The global Acute Vulvovaginal Candidiasis Treatment market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
By Market Verdors:
Mycovia Pharmaceuticals, Inc
Scynexis, Inc
Basilea Pharmaceutica Ltd
Astellas Pharma Inc
Grupo Ferrer Internacional, S.A
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc
Cidara Therapeutics, Inc
Amplyx Pharmaceuticals Inc
Pfizer, Inc.
By Types:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
By Applications:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2017-2028 & Sales with a thorough analysis of the market's competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2017-2028. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Acute Vulvovaginal Candidiasis Treatment Market Size Analysis from 2023 to 2028
1.5.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Acute Vulvovaginal Candidiasis Treatment Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Acute Vulvovaginal Candidiasis Treatment Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Acute Vulvovaginal Candidiasis Treatment Industry Impact
Chapter 2 Global Acute Vulvovaginal Candidiasis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Acute Vulvovaginal Candidiasis Treatment (Volume and Value) by Type
2.1.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption and Market Share by Type (2017-2022)
2.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue and Market Share by Type (2017-2022)
2.2 Global Acute Vulvovaginal Candidiasis Treatment (Volume and Value) by Application
2.2.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption and Market Share by Application (2017-2022)
2.2.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue and Market Share by Application (2017-2022)
2.3 Global Acute Vulvovaginal Candidiasis Treatment (Volume and Value) by Regions
2.3.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption by Regions (2017-2022)
4.2 North America Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
4.10 South America Acute Vulvovaginal Candidiasis Treatment Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Acute Vulvovaginal Candidiasis Treatment Market Analysis
5.1 North America Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
5.1.1 North America Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
5.2 North America Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
5.3 North America Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
5.4 North America Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
5.4.1 United States Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
5.4.2 Canada Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
5.4.3 Mexico Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 6 East Asia Acute Vulvovaginal Candidiasis Treatment Market Analysis
6.1 East Asia Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
6.1.1 East Asia Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
6.2 East Asia Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
6.3 East Asia Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
6.4 East Asia Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
6.4.1 China Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
6.4.2 Japan Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
6.4.3 South Korea Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 7 Europe Acute Vulvovaginal Candidiasis Treatment Market Analysis
7.1 Europe Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
7.1.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
7.2 Europe Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
7.3 Europe Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
7.4 Europe Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
7.4.1 Germany Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.2 UK Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.3 France Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.4 Italy Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.5 Russia Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.6 Spain Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.7 Netherlands Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.8 Switzerland Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
7.4.9 Poland Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 8 South Asia Acute Vulvovaginal Candidiasis Treatment Market Analysis
8.1 South Asia Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
8.1.1 South Asia Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
8.2 South Asia Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
8.3 South Asia Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
8.4 South Asia Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
8.4.1 India Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
8.4.2 Pakistan Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Analysis
9.1 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
9.1.1 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
9.2 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
9.3 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
9.4 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
9.4.1 Indonesia Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
9.4.2 Thailand Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
9.4.3 Singapore Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
9.4.4 Malaysia Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
9.4.5 Philippines Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
9.4.6 Vietnam Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
9.4.7 Myanmar Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 10 Middle East Acute Vulvovaginal Candidiasis Treatment Market Analysis
10.1 Middle East Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
10.1.1 Middle East Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
10.2 Middle East Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
10.3 Middle East Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
10.4 Middle East Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
10.4.1 Turkey Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.3 Iran Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.5 Israel Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.6 Iraq Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.7 Qatar Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.8 Kuwait Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
10.4.9 Oman Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 11 Africa Acute Vulvovaginal Candidiasis Treatment Market Analysis
11.1 Africa Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
11.1.1 Africa Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
11.2 Africa Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
11.3 Africa Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
11.4 Africa Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
11.4.1 Nigeria Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
11.4.2 South Africa Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
11.4.3 Egypt Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
11.4.4 Algeria Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
11.4.5 Morocco Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 12 Oceania Acute Vulvovaginal Candidiasis Treatment Market Analysis
12.1 Oceania Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
12.2 Oceania Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
12.3 Oceania Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
12.4 Oceania Acute Vulvovaginal Candidiasis Treatment Consumption by Top Countries
12.4.1 Australia Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
12.4.2 New Zealand Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 13 South America Acute Vulvovaginal Candidiasis Treatment Market Analysis
13.1 South America Acute Vulvovaginal Candidiasis Treatment Consumption and Value Analysis
13.1.1 South America Acute Vulvovaginal Candidiasis Treatment Market Under COVID-19
13.2 South America Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Types
13.3 South America Acute Vulvovaginal Candidiasis Treatment Consumption Structure by Application
13.4 South America Acute Vulvovaginal Candidiasis Treatment Consumption Volume by Major Countries
13.4.1 Brazil Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.2 Argentina Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.3 Columbia Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.4 Chile Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.5 Venezuela Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.6 Peru Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
13.4.8 Ecuador Acute Vulvovaginal Candidiasis Treatment Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Acute Vulvovaginal Candidiasis Treatment Business
14.1 Mycovia Pharmaceuticals, Inc
14.1.1 Mycovia Pharmaceuticals, Inc Company Profile
14.1.2 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Specification
14.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Scynexis, Inc
14.2.1 Scynexis, Inc Company Profile
14.2.2 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Specification
14.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Basilea Pharmaceutica Ltd
14.3.1 Basilea Pharmaceutica Ltd Company Profile
14.3.2 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Specification
14.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Astellas Pharma Inc
14.4.1 Astellas Pharma Inc Company Profile
14.4.2 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Specification
14.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Grupo Ferrer Internacional, S.A
14.5.1 Grupo Ferrer Internacional, S.A Company Profile
14.5.2 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Specification
14.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Pacgen Life Science Corporation
14.6.1 Pacgen Life Science Corporation Company Profile
14.6.2 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Specification
14.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 NovaDigm Therapeutics, Inc
14.7.1 NovaDigm Therapeutics, Inc Company Profile
14.7.2 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Specification
14.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Cidara Therapeutics, Inc
14.8.1 Cidara Therapeutics, Inc Company Profile
14.8.2 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Specification
14.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Amplyx Pharmaceuticals Inc
14.9.1 Amplyx Pharmaceuticals Inc Company Profile
14.9.2 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Specification
14.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Pfizer, Inc.
14.10.1 Pfizer, Inc. Company Profile
14.10.2 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Specification
14.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Acute Vulvovaginal Candidiasis Treatment Market Forecast (2023-2028)
15.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Acute Vulvovaginal Candidiasis Treatment Value and Growth Rate Forecast (2023-2028)
15.2 Global Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Acute Vulvovaginal Candidiasis Treatment Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Acute Vulvovaginal Candidiasis Treatment Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Acute Vulvovaginal Candidiasis Treatment Consumption Forecast by Type (2023-2028)
15.3.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Forecast by Type (2023-2028)
15.3.3 Global Acute Vulvovaginal Candidiasis Treatment Price Forecast by Type (2023-2028)
15.4 Global Acute Vulvovaginal Candidiasis Treatment Consumption Volume Forecast by Application (2023-2028)
15.5 Acute Vulvovaginal Candidiasis Treatment Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
Price : US$ 3500 |
Date : Aug 2024 |
Category : Services |
Pages : 174 |
Price : US$ 3500 |
Date : Aug 2024 |
Category : Services |
Pages : 129 |